COMMUNIQUÉS West-GlobeNewswire

Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting

16/10/2018 - 14:00

Top-line Results to be Released as a Late-Breaking Presentation SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that data will be presented from a phase 2b trial of its small molecule Wnt [...]

Inspire Medical Systems, Inc. to Report Third Quarter 2018 Financial Results November 6, 2018

16/10/2018 - 14:00

MINNEAPOLIS, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (“Inspire”) (NYSE: INSP), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]

Progressive Care Inc. Announces 40% Year-Over-Year Increase in Prescriptions Filled and Continued Strong Revenues in September 2018

16/10/2018 - 14:00

MIAMI, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced further growth year-over-year in both revenue and number of [...]

Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer

16/10/2018 - 14:00

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Tabula Rasa HealthCare President Orsula V. Knowlton Receives Mid-Atlantic Women’s Leadership Award

16/10/2018 - 14:00

MOORESTOWN, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare (NASDAQ: TRHC), President and Chief Marketing and Business Development Officer, Orsula V. Knowlton, PharmD, MBA received the CEO Report “Mid- [...]

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

16/10/2018 - 14:00

Vaccination complete in 1,537 subjects in PROTECT Phase 3 study No vaccine-related adverse events have been observed to-date Top-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- VBI [...]

Incysus Therapeutics to Present at the 2018 Bio Investor Forum

16/10/2018 - 14:00

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, [...]

Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168

16/10/2018 - 14:00

-- Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system -- SOUTH SAN FRANCISCO, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma [...]

Cancer Genetics Issues Letter to Shareholders

16/10/2018 - 14:00

RUTHERFORD, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the [...]

Medovex Corporation Announces Definitive Agreement to Acquire the Pulmonary Biomedical Services and Patient Delivery Platform of Regenerative Medicine Solutions, LLC

16/10/2018 - 14:00

ALPHARETTA, Ga., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex”) announced today that it has signed a definitive agreement to acquire the pulmonary biomedical services and patient [...]

Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of XERMELO® (Telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination With Somatostatin Analog Therapy

16/10/2018 - 14:00

Approval Enables Availability of First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs Alone THE [...]

Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues

16/10/2018 - 13:47

Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017 NEW HAVEN, Conn., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Specialty [...]

AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

16/10/2018 - 13:30

On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “ [...]

Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

16/10/2018 - 13:30

Investigational New Drug Applications Recently Filed for Two New Cardiac Programs: Cardiac Troponin Activator and Cardiac Myosin Inhibitor Advance Toward Phase 1 Studies Clinical Trial Design Announced for METEORIC-HF, [...]

Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress

16/10/2018 - 13:30

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical data from its SL- [...]

resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs

16/10/2018 - 13:12

RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition to decreasing the incidence of laboratory-confirmed [...]

BeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSF

16/10/2018 - 13:06

Evidence of Neutrophil Demargination and Bone Marrow Transit Time Reduction by Plinabulin Presented at Joint Meeting of the Society for Leukocyte Biology and International Endotoxin and Innate Immunity Society NEW YORK [...]

Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy

16/10/2018 - 13:05

Conference call and webcast to be held today at 8:00 AM Eastern Time NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel [...]

Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018

16/10/2018 - 13:05

IRVING, Texas, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s progress in developing [...]